Patents Assigned to AstraZeneca
  • (3-(4-(AMINOMETHYL)PHENOXY OR PHENYLTHIO)AZETIDIN-1-YL)(5-PHENYL-1,3,4-OXADIAZOL-2-YL)METHANONE COMPOUNDS
    Publication number: 20120010189
    Abstract: Disclosed herein are azetidinyl compounds of formula I, as described herein, pharmaceutical compositions comprising an azetidinyl compound, and a method of using an azetidinyl compound in the treatment or prophylaxis of a melanin-concentrating hormone related disease or condition.
    Type: Application
    Filed: July 5, 2011
    Publication date: January 12, 2012
    Applicant: AstraZeneca AB
    Inventors: Susanne Doris Margit Bökman-Winiwarter, Marlene FREDENWALL, Carl Anders Hogner, Lars Anders Mikael Johansson, Robert Andrew Judkins, Lanna Li, Björn Christian Ingvar Löfberg, Sverker Von Unge
  • Substituted indoles
    Patent number: 8093278
    Abstract: The present invention relates to substituted indoles of formula (I), useful as pharmaceutical compounds for treating respiratory disorders.
    Type: Grant
    Filed: April 28, 2010
    Date of Patent: January 10, 2012
    Assignee: AstraZeneca AB
    Inventors: Timothy Birkinshaw, Roger Bonnert, Tony Cook, Rukhsana Rasul, Hitesh Sanganee, Simon Teague
  • Crystalline polymorphic form of glucokinase activator
    Patent number: 8093252
    Abstract: A new polymorphic form of 3-{[5-(azetidin-1-ylcarbonyl)pyrazin-2-yl]oxy}-5-{[(1S)-1-methyl-2-(methyloxy)ethyl]oxy}-N-(5-methylpyrazin-2-yl)benzamide, processes for making it and its use as an activator of glucokinase are described.
    Type: Grant
    Filed: February 15, 2010
    Date of Patent: January 10, 2012
    Assignee: AstraZeneca AB
    Inventors: Sharon Ann Bowden, David Peter Hoile, Karin Lövqvist
  • Compounds useful for the treatment of conditions associated with weight gain
    Patent number: 8093248
    Abstract: The present application relates to new compounds of formula (I), to pharmaceutical compositions comprising the compounds, to processes for their preparation, and to the use of the compounds as leptin receptor modulator mimetics in the preparation of medicaments against conditions associated with weight gain, type 2 diabetes and dyslipidemias.
    Type: Grant
    Filed: December 5, 2008
    Date of Patent: January 10, 2012
    Assignee: AstraZeneca AB (PUBL)
    Inventors: Joseph W. Boyd, Giles A. Brown, Michael Higginbottom, Viet-Anh Anne Horgan (Nee Nguyen), Jaqueline Ouzman, Iain Simpson
  • Benzimidazole derivatives
    Patent number: 8093402
    Abstract: Provided herein are compounds in accord with Formula I: that are useful in the treatment of pain.
    Type: Grant
    Filed: February 8, 2011
    Date of Patent: January 10, 2012
    Assignee: AstraZeneca AB
    Inventors: William Brown, Shawn Johnstone, Denis Labrecque
  • AMIDE DERIVATIVES BEARING A CYCLOPROPYLAMINOACARBONYL SUBSTITUENT USEFUL AS CYTOKINE INHIBITORS
    Publication number: 20120004243
    Abstract: The invention concerns a compound of the Formula (I), wherein Qa is heteroaryl and is substituted with halogeno; R1 and R2 are hydrogen; and Qb is phenyl or heteroaryl, and Qb may optionally bear 1 or 2 substituents selected from hydroxy, halogeno and (1-6C)alkyl, or a pharmaceutically-acceptable salt thereof; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical conditions mediated by cytokines.
    Type: Application
    Filed: April 5, 2011
    Publication date: January 5, 2012
    Applicant: AstraZeneca AB
    Inventors: Dearg Sutherland Brown, John Graham Cumming, Ian Alun Nash
  • 5,7-disubstituted thiazolo[4,5-D]pyrimidines for the selective inhibition of chemokine receptors
    Patent number: 8088780
    Abstract: There are disclosed novel 5,7-disubstituted [1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one derivatives of formula (I) wherein R1, R2, R3, R4 and R5 are as defined in the specification, and pharmaceutically acceptable salts thereof, together with processes for their preparation, pharmaceutical compositions comprising them and their use in therapy. The compounds of formula (I) are CX3CR1 receptor antagonists and are thereby particularly useful in the treatment or prophylaxis of neurodegenerative disorders, demyelinating disease, cardio- and cerebrovascular atherosclerotic disorders, peripheral artery disease, rheumatoid arthritis, pulmonary diseases such as COPD, asthma or pain.
    Type: Grant
    Filed: April 3, 2006
    Date of Patent: January 3, 2012
    Assignee: AstraZeneca AB
    Inventors: Gunnar Nordvall, Colin Ray, Tobias Rein, Daniel Sohn
  • 4-(3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
    Patent number: 8088784
    Abstract: This invention relates to novel compounds having the formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment for cancer.
    Type: Grant
    Filed: February 26, 2010
    Date of Patent: January 3, 2012
    Assignee: AstraZeneca AB
    Inventors: Xiaomei Feng, Huiping Guan, Ying Kang, Stephanos Ioannidis, Bo Peng, Mei Su, Bin Wang, Tao Wang, Hai-Jun Zhang
  • Crystalline 4-(3-chloro-2-fluoroanilino)-7 methoxy-6-{[1-(N-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline difumarate form A
    Patent number: 8088782
    Abstract: 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[1-(N-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline difumarate, pharmaceutical compositions containing the difumarate, the use of the difumarate in the treatment of hyperproliferative disorders such as cancer and processes for the manufacture of the difumarate are described.
    Type: Grant
    Filed: May 11, 2009
    Date of Patent: January 3, 2012
    Assignee: AstraZeneca AB
    Inventor: Andrew Hornby Dobson
  • Substituted Isoindoles
    Publication number: 20110319426
    Abstract: The present invention relates to novel compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of A?-related pathologies such as Downs syndrome, ?-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with diseases such as Alzheimer disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.
    Type: Application
    Filed: September 6, 2011
    Publication date: December 29, 2011
    Applicant: ASTRAZENECA AB
    Inventors: Jörg HOLENZ, Sofia KARLSTRÖM, Karin KOLMODIN, Johan LINDSTRÖM, Laszlo RAKOS, Didier ROTTICCI, Peter SÖDERMAN, Britt-Marie SWAHN, Stefan VON BERG
  • Pharmaceutical Compositions
    Publication number: 20110319384
    Abstract: The present invention provides methods of treatment with a pharmaceutical composition, more particularly a sustained release pharmaceutical composition, comprising 11-[4-[2-(2-hydroxyethoxy)ethyl]-1-piperazinyl]dibenzo-[b,f][1,4]thiazepine or a pharmaceutically acceptable salt thereof, as well as new and improved methods for treating a variety of psychological disorders and conditions including, but not limited to, Mood Disorders and Anxiety Disorders and for treating one or more of the symptoms of these disorders.
    Type: Application
    Filed: September 9, 2011
    Publication date: December 29, 2011
    Applicant: AstraZeneca AB
    Inventors: Hans Eriksson, Martin Brecher, Rohini Chitra, Joan Shaw, Mårten Vågerö, Ellis Wilson
  • Extended Release Formulations Comprising Quetiapine and Methods for Their Manufacture
    Publication number: 20110319383
    Abstract: The present invention relates to extended release formulations of quetiapine and its pharmaceutically acceptable salts. The formulations comprise polymers, preferably hydroxypropyl methylcellulose of different viscosities, selected to cause the formulations to conform to preselected quetiapine release profiles. A process for the manufacture of said formulations is also disclosed.
    Type: Application
    Filed: November 16, 2007
    Publication date: December 29, 2011
    Applicant: ASTRAZENECA AB
    Inventors: Daniel Brown, Donna Caster, Brian Clark, Sandra Hopkins, Jennifer Llewelyn, Lisa Martin, Elizabeth Meehan, Robert Timko, Husheng Yang
  • Inhaler
    Patent number: 8082918
    Abstract: A breath-actuated inhaler for delivery of a medicament by inhalation from a canister (2) which is compressible to deliver a dose of medicament. The inhaler comprises a housing (1) for holding a canister (2) and including a mouthpiece (5) for delivery of a dose of medicament from a canister (2) held in the housing; and an actuation mechanism (6) for compressing a canister (2) held in the housing (1) in response to inhalation at the mouthpiece (5). The housing includes two separable portions (19, 20). The first housing portion (19) mounts the actuation mechanism (6). The second housing portion (20) houses the mouthpiece (5) and a duct (24) shaped to direct an inhalation flow from the mouthpeice (5) to the first housing portion (19) for triggering the actuation mechanism (6). The duct (24) and the mouthpiece (5) are integrally formed and separable from the second housing portion (20).
    Type: Grant
    Filed: March 16, 2001
    Date of Patent: December 27, 2011
    Assignee: AstraZeneca AB
    Inventors: Rob Jansen, Lars Knudsen, Henrik Vilstrup
  • PROCESS FOR THE PREPARATION OF 1-[5-(3-CHLORO-PHENYL)-ISOOXAZOL-3-YL]-ETHANONE AND (R)-1-[5-(3-CHLORO-PHENYL)-ISOOXAZOL-3-YL]-ETHANOL
    Publication number: 20110313172
    Abstract: The present invention provides a process for the preparation of the compound 1-[5-(3-chloro-phenyl)-isooxazol-3-yl]-ethanone: Wherein the compound 5-(3-chlorophenyl)-isooxazol-3-carboxylate is reacted with CH3MgX. The present invention also provides a process for the preparation of (R)-1-[5-(3-chloro-phenyl)-isooxazol-3-yl]-ethanol: Wherein 1-[5-(3-chloro-phenyl)-isooxazol-3-yl]-ethanone is reduced to (R)-1-[5-(3-chloro-phenyl)-isooxazol-3-yl]-ethanol.
    Type: Application
    Filed: December 11, 2009
    Publication date: December 22, 2011
    Applicant: ASTRAZENECA AB
    Inventors: Hans Åström, Elfyn Jones
  • CHEMICAL COMPOUNDS
    Publication number: 20110306613
    Abstract: There is provided pyrimidinyl compounds of Formula (I), wherein: R2 is or pharmaceutically acceptable salts thereof, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Application
    Filed: June 9, 2011
    Publication date: December 15, 2011
    Applicant: ASTRAZENECA AB
    Inventors: Kevin Michael Foote, Johannes Wilhelmus Maria Nissink, Paul Turner
  • PROCESSES FOR THE MANUFACTURE OF 3--PYRIDINE, 4-METHYL-3-METHYLTHIO-5-(3-PYRIDYL)-L,2,4-TRIAZOLE, AND (1R)-1-[2-(3-METHYLPHENYL)-2H-TETRAZOL-5-YL]ETHANOL
    Publication number: 20110306768
    Abstract: The present invention provides a process for the manufacture of the compound 3-{4-methyl-5-[(1R)-1-(2-(3-methylphenyl-2H-tetrazol-5-yl)-ethoxy]-4H-[1,2,4]triazol-3-yl}-pyridine of formula 14 wherein a) the compound 3-(5-methane-sulfonyl-4-methyl-4H-1,2,4-triazol-3-yl)-pyridine of formula 6 and the compound (1R)-[2-(3-methylphenyl)-2H-tetrazol-5-yl]ethanol of formula 13 are dissolved in an aprotic solvent, whereafter an alkoxide base is added, providing the compound of formula 14. The invention also provides methods for manufacturing 3-(5-methanesulfonyl-4-methyl-4H-1,2,4-triazol-3-yl)-pyridine and (1R)-1-[2-(3-methylphenyl)-2H-tetrazol-5-yl]ethanol.
    Type: Application
    Filed: December 11, 2009
    Publication date: December 15, 2011
    Applicant: ASTRAZENECA AB
    Inventors: Jones Elfyn, Ulf G. Larsson
  • 9-SUBSTITUTED 8-OXOADENINE COMPOUND
    Publication number: 20110306610
    Abstract: The present invention provides an 8-oxoadenine compound having immunemodulating activities such as an interferon inducing activity and useful as an antiviral agent and antiallergic agent, which is represented by the following formula (1): [wherein the ring A represents a 6-10 membered aromatic carbocyclic ring and the like, R represents a halogen atom, an alkyl group and the like, n represents an integer of 0-2, Z1 represents alkylene, X2 represents oxygen atom, sulfur atom, SO2, NR5, CO, CONR5, NR5CO and the like, Y1, Y2 and Y3 represent independently a single bond or an alkylene group, X1 represents oxygen atom, sulfur atom, NR4 (R4 is hydrogen atom or an alkyl group) or a single bond, R2 represents a substituted or unsubstituted alkyl group, R1 represents hydrogen atom, hydroxy group, an alkoxy group, an alkoxycarbonyl group or a haloalkyl group] or its pharmaceutically acceptable salt.
    Type: Application
    Filed: July 20, 2011
    Publication date: December 15, 2011
    Applicants: AstraZeneca Aktiebolag, Dainippon Sumitomo Pharma Co., Ltd.
    Inventors: Ayumu KURIMOTO, Kazuki Hashimoto, Yoshiaki Isobe, Stephen Brough, Ian Millichip, Hiroki Wada, Roger Bonnert, Thomas Mcinally
  • Form of S-omeprazole
    Patent number: 8076361
    Abstract: The present invention relates to a novel form of the (?)-enantiomer of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2 -pyridinyl)-methyl]sulfinyl]-1H-benzimidazole, i.e. S-omeprazole. More specifically, it relates to a novel form of the magnesium salt of the S-enantiomer of omeprazole trihydrate. The present invention also relates to processes for preparing such a form of the magnesium salt of S-omeprazole and pharmaceutical compositions containing it. Furthermore, the present invention also relates to new intermediates used in the process.
    Type: Grant
    Filed: May 21, 2010
    Date of Patent: December 13, 2011
    Assignee: AstraZeneca AB
    Inventors: Hanna Cotton, Anders Kronström, Anders Mattson, Eva Möller
  • Chemical process 632
    Patent number: 8076481
    Abstract: A process for preparing pharmaceutically active compounds of formula (I) or a salt thereof wherein R1, n, m, R3, R6, X1, X2, X3 and X4 are as defined in the specification, is described. Novel intermediates are also described and claimed.
    Type: Grant
    Filed: February 15, 2010
    Date of Patent: December 13, 2011
    Assignee: AstraZeneca AB
    Inventors: Michael Butters, Jeffrey Crabb, Philip Hopes, Bharti Patel
  • Process for the Manufacture of the Calcium Salt of Rosuvastatin (E)-7-[4-(4-Fluorophenyl)-6-Isopropyl-2-[Methyl(Methylsulfonyl)Amino]-Pyrimidin-5-yl](3R,5S)-3,5-Dihydroxyhept-6-Enoic Acid and Crystalline Intermediates Thereof
    Publication number: 20110301348
    Abstract: A process for the manufacture of the calcium salt of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid, useful as an HMGCoA reductase inhibitor, from a compound of the formula (7) wherein A is an acetal or ketal protecting group and R is alkyl, via isolated crystalline compounds of the formula (8) or of formula (10) is described. Crystalline intermediates of formulae 7, 8 and 10 are also described.
    Type: Application
    Filed: July 19, 2011
    Publication date: December 8, 2011
    Applicant: AstraZeneca UK Limited
    Inventors: Tetsuo OKADA, John HORBURY, David Dermot Patrick LAFFAN